Deirdre Evens
Known title: DirectorCIK: 0001401237
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
AI boom boosts IRM as REITs gain from data demand. Iron Mountain is highlighted in a Yahoo article that links the rapid growth of AI to increased demand for data center space, benefiting several REITs including IRM. The company also announced its third‑quarter 2026 earnings release and conference call, giving investors a chance to review its performance. A separate piece noted that REITs overall are outperforming the market, which may support IRM’s position in the sector.
Transaction History
| REG | ▲ Buy | Option Exercise | 1,736 | — | 5/11/2026 | View on chart |
| REG | ▲ Buy | Option Exercise | 71 | — | 5/11/2026 | View on chart |
| REG | ▲ Buy | Option Exercise | 2,115 | — | 5/5/2025 | View on chart |
| REG | ▲ Buy | Option Exercise | 85 | — | 5/5/2025 | View on chart |
| REG | ▲ Buy | Option Exercise | 2,096 | — | 5/3/2024 | View on chart |
| REG | ▲ Buy | Option Exercise | 67 | — | 5/3/2024 | View on chart |
| REG | ▲ Buy | Grant | 465 | — | 2/12/2024 | View on chart |
| REG | ▲ Buy | Grant | 455 | — | 11/1/2023 | View on chart |
| REG | ▲ Buy | Grant | 483 | — | 8/1/2023 | View on chart |
| REG | ▲ Buy | Grant | 457 | — | 5/4/2023 | View on chart |
| REG | ▲ Buy | Option Exercise | 79 | — | 5/3/2023 | View on chart |
| REG | ▲ Buy | Option Exercise | 1,817 | — | 5/3/2023 | View on chart |
| REG | ▲ Buy | Grant | 468 | — | 2/8/2023 | View on chart |
| REG | ▲ Buy | Grant | 470 | — | 11/3/2022 | View on chart |
| REG | ▲ Buy | Grant | 434 | — | 8/5/2022 | View on chart |
| REG | ▲ Buy | Option Exercise | 2,000 | — | 5/9/2022 | View on chart |
| REG | ▲ Buy | Option Exercise | 71 | — | 5/9/2022 | View on chart |
| REG | ▲ Buy | Grant | 411 | — | 4/29/2022 | View on chart |
| IRM | ▼ Sell | Open Market | 29,037 | $1.6M | 3/29/2022 | View on chart |
| IRM | ▲ Buy | Option Exercise | 29,037 | $979K | 3/29/2022 | View on chart |
| IRM | ▼ Sell | Open Market | 2,658 | $133K | 3/2/2022 | View on chart |
| IRM | ▼ Sell | Open Market | 7,828 | $391K | 3/1/2022 | View on chart |
| IRM | ▲ Buy | Option Exercise | 9,549 | $0 | 3/1/2022 | View on chart |
| IRM | ▼ Sell | Tax Withholding | 4,234 | $210K | 3/1/2022 | View on chart |
| IRM | ▲ Buy | Option Exercise | 15,612 | $0 | 2/24/2022 | View on chart |
| IRM | ▼ Sell | Tax Withholding | 4,713 | $214K | 2/24/2022 | View on chart |
| IRM | ▼ Sell | Tax Withholding | 698 | $30K | 2/22/2022 | View on chart |
| IRM | ▼ Sell | Tax Withholding | 1,364 | $58K | 2/22/2022 | View on chart |
| IRM | ▲ Buy | Option Exercise | 4,438 | $0 | 2/22/2022 | View on chart |
| IRM | ▲ Buy | Option Exercise | 2,380 | $0 | 2/22/2022 | View on chart |
| REG | ▲ Buy | Grant | 398 | — | 2/11/2022 | View on chart |
| IRM | ▲ Buy | Option Exercise | 32,087 | $1.0M | 12/28/2021 | View on chart |
| IRM | ▼ Sell | Open Market | 32,087 | $1.7M | 12/28/2021 | View on chart |
| IRM | ▲ Buy | Option Exercise | 39,441 | $1.2M | 12/16/2021 | View on chart |
| IRM | ▼ Sell | Open Market | 39,441 | $2.0M | 12/16/2021 | View on chart |
| REG | ▲ Buy | Grant | 434 | — | 10/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Regency Centers Faces Analyst Adjustments Amid Rate Concerns
Regency Centers is navigating a challenging environment as broader REITs face pressure from high interest rates. Recent analyst actions include Truist assuming coverage at a Buy rating and Barclays lowering its price target to $85 while maintaining an Overweight stance. The company is also preparing for its third-quarter 2026 earnings call, with the stock currently trading near its 52-week low.
Regency Centers Faces Analyst Adjustments Amid Rate Concerns. Regency Centers is navigating a challenging environment as broader REITs face pressure from high interest rates. Recent analyst actions include Truist assuming coverage at a Buy rating and Barclays lowering its price target to $85 while maintaining an Overweight stance. The company is also preparing for its third-quarter 2026 earnings call, with the stock currently trading near its 52-week low.